MedPath

Cognitive-behavioral (CBT) in ESRD Patients With Depression

Not Applicable
Completed
Conditions
Depression
Quality of Life
Kidney Failure, Chronic
Interventions
Behavioral: Cognitive-behavioral group therapy
Registration Number
NCT02011139
Lead Sponsor
Seoul National University Boramae Hospital
Brief Summary

Depression is common in end-stage renal disease (ESRD) patients and has a negative effect on the quality of life, functional ability, and mortality, with a prevalence rate as high as 20-25%. However, it is hard to use anti-depressant due to the safety issue, and there has been little data so far particularly in terms of randomized clinical trials. Here, we investigate the effect of cognitive-behavioral group therapy for enhancing mental health and quality of life in patients with ESRD.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
15
Inclusion Criteria
  • Patients with end-stage renal disease : on hemodialysis more than 3 months
  • Patients with BDI-II score >= 15 points
  • Adult with age >= 20 years old
  • Patients who were able to understand and willing to sign the written informed consent
Exclusion Criteria
  • Patients on hemodialysis due to acute kidney injury
  • Patients who are on admission
  • Patients who are undergoing chemotherapy or radiation therapy due to progressive malignant disease
  • Patients who are planning kidney transplantation within few months
  • Patients with cognitive dysfunction, mental retardation, and drug addict
  • Patients who are unavailable for adequate communication with researchers
  • Patients who changed anti-depressive agent or dose within 2 months before/after the trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Group BCognitive-behavioral group therapy12 sessions of Cognitive-behavioral group therapy in the second 12 weeks
Group ACognitive-behavioral group therapy12 sessions of Cognitive-behavioral group therapy in the first 12 weeks
Primary Outcome Measures
NameTimeMethod
Beck Depression Inventory-II (BDI-II) score3 months
Secondary Outcome Measures
NameTimeMethod
Secondary assessment tools for depression,anxiety, and quality of life3 months

Additional anti-depressant use after trial

Trial Locations

Locations (1)

Seoul National University Boramae Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath